FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
FDA decision: Ivonescimab by Summit Therapeutics (in 2026) Live odds across 1 market: a full approval or an accelerated approval at 92¢. Resolves Jan 1, 2027. N
Resolves Jan 1, 2027
- a full approval or an accelerated approval: Yes 92¢ (kalshi)
TRADING OPEN
8sFDA decision: Ivonescimab by Summit Therapeutics (in 2026)
Resolves Jan 1, 2027
Total Volume
$8.1K
+$56 (24h)
Active Markets
1
Across 1 platforms
Frontrunner
92¢
a full approval or an accelerated approval
Biggest Mover 24h
-2¢
a full approval or an accelerated approval
Arb Opportunities
0
None detected
All Markets
| # | ||||||
|---|---|---|---|---|---|---|
| 1 | 92¢ | 92¢ | $8.1K+$56 24h | -2¢ | — |
Implied Probability
Consensus across platformsEvent Info
Whale Activity
Loading...